Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GDNF family receptor alpha-4 (GFRA4) is a member of the glial cell line-derived neurotrophic factor receptor alpha family, functioning as a glycosylphosphatidylinositol (GPI)-linked cell surface receptor, most notably for the neurotrophic factor persephin. GFRA4 acts as a co-receptor for ligand-dependent activation of the receptor tyrosine kinase RET, supporting signal transduction important for neuronal survival, differentiation, and nervous system development[1][2][3][4]. It is implicated in disorders such as multiple endocrine neoplasia type 2, familial medullary thyroid carcinoma, and Hirschsprung disease; its aberrant expression or altered regulation may disrupt normal neurocrine signaling and developmental processes. GFRA4's precise physiological and pathophysiological roles continue to be elucidated, with a growing interest in how its modulation could influence disease outcomes in neurodevelopmental, neoplastic, and possibly immune-related conditions[1][2][3][4].
Ligand-induced receptor activation: Persephin binds GFRA4, which acts as a co-receptor to activate the RET tyrosine kinase, initiating downstream signaling pathways important for cell survival, proliferation, and differentiation[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GDNF family receptor alpha-4 (GFRA4).